Review Article: The Comparison of Effectiveness and Side Effects of Pembrolizumab in Combination with Chemotherapy versus Single Chemotherapy in the Treatment of Non-Small Cell Lung Cancer (NSCLC) / Review Artikel: Perbandingan Efektivitas dan Efek Samping Pembrolizumab Kombinasi Kemoterapi Dengan Kemoterapi Tunggal Dalam Pengobatan Non-Small Cell Lung Cancer (NSCLC)

This review article aims to compare the effectiveness and side effects of pembrolizumab combined with chemotherapy versus chemotherapy alone in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC). A systematic review was conducted using literature published between 2015 and 2024. Relevant studies were identified through databases such as Google Scholar, using keywords like "Pembrolizumab," "Side Effects," "Effectiveness," "Overall Survival (OS)," and "Progression-Free Survival (PFS)." The results showed that pembrolizumab combined with chemotherapy significantly improved Overall Survival (OS) and Progression-Free Survival (PFS) compared to chemotherapy alone. However, this combination therapy was associated with a higher frequency of side effects, such as pneumonitis and hypothyroidism. In conclusion, pembrolizumab combined with chemotherapy offers superior efficacy in prolonging survival and controlling disease progression in advanced NSCLC. However, its use requires careful patient selection and close monitoring of toxicity. These findings support pembrolizumab as a promising first-line therapy for advanced NSCLC.

Artikel tinjauan ini bertujuan untuk membandingkan efektivitas dan efek samping pembrolizumab kombinasi kemoterapi dengan kemoterapi tunggal dalam pengobatan kanker Non-Small Cell Lung Cancer (NSCLC) stadium lanjut. Tinjauan sistematis dilakukan dengan menggunakan literatur yang diterbitkan antara tahun 2015 hingga 2024. Studi yang relevan diidentifikasi melalui basis data seperti Google Scholar, dengan menggunakan kata kunci "Pembrolizumab," "Efek Samping," "Efektivitas," "Overall Survival (OS)," dan "Progression-Free Survival (PFS)." Hasil menunjukkan bahwa pembrolizumab kombinasi kemoterapi meningkatkan Overall Survival (OS) dan Progression-Free Survival (PFS) dibandingkan dengan kemoterapi tunggal. Namun, terapi kombinasi ini memiliki frekuensi efek samping yang lebih tinggi, seperti pneumonitis dan hipotiroidisme. Kesimpulannya, pembrolizumab kombinasi kemoterapi memberikan efikasi superior dalam memperpanjang kelangsungan hidup dan mengendalikan progresi penyakit pada NSCLC stadium lanjut. Namun, penggunaannya memerlukan seleksi pasien yang cermat dan pemantauan ketat terhadap toksisitas. Temuan ini mendukung pembrolizumab sebagai terapi lini pertama yang menjanjikan untuk NSCLC stadium lanjut.